[go: up one dir, main page]

NO20052496D0 - Selected CGRP antagonists, methods for their preparation and use thereof as drugs. - Google Patents

Selected CGRP antagonists, methods for their preparation and use thereof as drugs.

Info

Publication number
NO20052496D0
NO20052496D0 NO20052496A NO20052496A NO20052496D0 NO 20052496 D0 NO20052496 D0 NO 20052496D0 NO 20052496 A NO20052496 A NO 20052496A NO 20052496 A NO20052496 A NO 20052496A NO 20052496 D0 NO20052496 D0 NO 20052496D0
Authority
NO
Norway
Prior art keywords
drugs
preparation
methods
cgrp antagonists
selected cgrp
Prior art date
Application number
NO20052496A
Other languages
Norwegian (no)
Other versions
NO20052496L (en
Inventor
Eckhart Bauer
Henri Nico Doods
Klaus Rudolf
Stephan Georg Mueller
Dirk Stenkamp
Philipp Lustenberger
Kirsten Arndt
Alexander Dreyer
Marcus Schindler
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20052496D0 publication Critical patent/NO20052496D0/en
Publication of NO20052496L publication Critical patent/NO20052496L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20052496A 2002-10-25 2005-05-24 Selected CGRP antagonists, methods for their preparation and use thereof as drugs. NO20052496L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10250080A DE10250080A1 (en) 2002-10-25 2002-10-25 Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
PCT/EP2003/011762 WO2004037810A1 (en) 2002-10-25 2003-10-23 Selected cgrp antagonists, method for production and use thereof as medicament

Publications (2)

Publication Number Publication Date
NO20052496D0 true NO20052496D0 (en) 2005-05-24
NO20052496L NO20052496L (en) 2005-06-24

Family

ID=32103086

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052496A NO20052496L (en) 2002-10-25 2005-05-24 Selected CGRP antagonists, methods for their preparation and use thereof as drugs.

Country Status (27)

Country Link
EP (1) EP1558600B1 (en)
JP (1) JP4401296B2 (en)
KR (1) KR20050074970A (en)
CN (1) CN1708493A (en)
AR (1) AR041718A1 (en)
AT (1) ATE394392T1 (en)
AU (1) AU2003276156A1 (en)
BR (1) BR0315665A (en)
CA (1) CA2503455A1 (en)
CO (1) CO5570704A2 (en)
DE (2) DE10250080A1 (en)
DK (1) DK1558600T3 (en)
EA (1) EA009219B1 (en)
EC (1) ECSP055747A (en)
ES (1) ES2306918T3 (en)
HR (1) HRP20050364A2 (en)
IL (1) IL168056A0 (en)
MX (1) MXPA05004375A (en)
NO (1) NO20052496L (en)
PE (1) PE20040592A1 (en)
PL (1) PL376450A1 (en)
RS (1) RS20050311A (en)
TW (1) TW200413317A (en)
UA (1) UA79323C2 (en)
UY (1) UY28034A1 (en)
WO (1) WO2004037810A1 (en)
ZA (1) ZA200502248B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963868A1 (en) * 1999-12-30 2001-07-12 Boehringer Ingelheim Pharma New substituted piperidines, pharmaceutical compositions containing these compounds and process for their preparation
EP1481965B1 (en) * 2002-02-07 2015-07-29 Hitoshi Endo Aromatic amino acid derivatives and medicinal compositions
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
WO2005004869A1 (en) * 2003-07-07 2005-01-20 Boehringer Ingelheim International Gmbh Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
US7569578B2 (en) 2003-12-05 2009-08-04 Bristol-Meyers Squibb Company Heterocyclic anti-migraine agents
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (en) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102004018795A1 (en) 2004-04-15 2005-10-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102004018796A1 (en) * 2004-04-15 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
WO2006031513A2 (en) * 2004-09-09 2006-03-23 Merck & Co., Inc. Aryl spirolactam cgrp receptor antagonists
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063752A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists to combat menopausal hot flashes
DE102004063753A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists in combination with other migraine medicines for the treatment of migraine
DE102004063755A1 (en) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of CGRP antagonists for the treatment and prevention of hot flushes in patients with prostate cancer
EP1770091A1 (en) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-antagonists, process for their preparation as well as their use as medicaments
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
CN101146799A (en) 2005-03-23 2008-03-19 贝林格尔·英格海姆国际有限公司 CGRP antagonists, processes for their preparation and their use as medicaments
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102005038831A1 (en) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New N-acylalkoxycarbonyl-piperidine derivatives, useful as CGRP antagonists, for treating e.g. headaches, cardiovascular disease, skin disorders, morphine tolerance, and inflammatory diseases such as osteoarthritis and allergic rhinitis
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
EP1770087A1 (en) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Selected CGRP antagonists, process for their preparation as well as their use as medicaments
EP1770086A1 (en) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG Selected CGRP antagonists, process for their preparation as well as their use as medicaments
DE102005050892A1 (en) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
DE102006017827A1 (en) * 2006-04-13 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg New crystalline compounds
MX2008015562A (en) * 2006-06-08 2008-12-17 Boehringer Ingelheim Int Treatment of gastrointestinal disorders with cgrp-antagonists.
DE102007038250A1 (en) * 2007-08-13 2009-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg New manufacturing process
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
CA2705405A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
CA2737348C (en) 2008-08-01 2015-12-08 Mitsui Chemicals Agro, Inc. Amide derivative, pest control agent containing the amide derivative, and pest controlling method
PT2396081T (en) 2009-02-16 2017-07-11 Nogra Pharma Ltd Alkylamido compounds and uses thereof
EP2811993B1 (en) 2012-02-09 2019-10-09 Nogra Pharma Limited Methods of treating fibrosis
US10870660B2 (en) 2016-07-28 2020-12-22 Shionogi & Co., Ltd. Nitrogen-containing condensed ring compounds having dopamine D3 antagonistic effect
DK3668853T3 (en) 2017-08-16 2021-12-06 Glaxosmithkline Ip Dev Ltd New connections
CA3089498A1 (en) 2018-01-26 2019-08-01 Shionogi & Co., Ltd. Condensed ring compounds having dopamine d3 receptor antagonistic effect
SI3921299T1 (en) 2019-02-08 2025-03-31 Nogra Pharma Limited Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525371A (en) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Benzimidazolinyl piperidine as CGRP ligand
DE19937304C2 (en) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Use of CGRP antagonists to combat menopausal hot flashes

Also Published As

Publication number Publication date
ZA200502248B (en) 2006-08-30
JP2006516244A (en) 2006-06-29
CO5570704A2 (en) 2005-10-31
DE10250080A1 (en) 2004-05-13
ATE394392T1 (en) 2008-05-15
JP4401296B2 (en) 2010-01-20
WO2004037810A1 (en) 2004-05-06
EP1558600A1 (en) 2005-08-03
EP1558600B1 (en) 2008-05-07
AR041718A1 (en) 2005-05-26
UY28034A1 (en) 2004-05-31
ECSP055747A (en) 2005-07-06
PE20040592A1 (en) 2004-10-27
HRP20050364A2 (en) 2006-05-31
CA2503455A1 (en) 2004-05-06
KR20050074970A (en) 2005-07-19
RS20050311A (en) 2007-08-03
EA009219B1 (en) 2007-12-28
ES2306918T3 (en) 2008-11-16
UA79323C2 (en) 2007-06-11
NO20052496L (en) 2005-06-24
PL376450A1 (en) 2005-12-27
AU2003276156A1 (en) 2004-05-13
BR0315665A (en) 2005-08-30
EA200500600A1 (en) 2006-02-24
DE50309807D1 (en) 2008-06-19
DK1558600T3 (en) 2008-09-01
CN1708493A (en) 2005-12-14
IL168056A0 (en) 2009-02-11
MXPA05004375A (en) 2005-07-05
TW200413317A (en) 2004-08-01

Similar Documents

Publication Publication Date Title
NO20052496D0 (en) Selected CGRP antagonists, methods for their preparation and use thereof as drugs.
NO20052493D0 (en) Selected CGRP antagonists, processes for their preparation and their use as pharmaceutical compositions.
DK1732917T3 (en) Selected CGRP antagonists, processes for their preparation, and their use as a drug
NO20052739D0 (en) CCR5 antagonists as drugs
IS2759B (en) CGRP receptor antagonists, drug preparations and use of the preparations for the manufacture of a drug
NO20035298D0 (en) CDK-inhibiting pyrimides, their preparation and their use as drugs
NO20053356L (en) Aminindazole derivatives and their use as kinase inhibitors.
NO20052855D0 (en) Phosphonoxycinazoline derivatives and their pharmaceutical use.
DK1532149T3 (en) 8- [3-Amino-piperiden-1-yl] -xanthines, their preparation and their use as a drug
NO20055525D0 (en) Tissue Protective Cytokine Receptor Complex Assay for Identifying Tissue Protective Compounds and Uses thereof
DK1534277T3 (en) Acylated, heteroaryl-fused cycloalkenylamines and their use as drugs
DK1500654T3 (en) Benzoxazinone derivatives, their preparation and their use as pharmaceuticals
NO20021799D0 (en) New cyclopropanes such as CGRP antagonists, drugs containing these compounds, and methods for their preparation
DK1667668T3 (en) Alphabeta3 and altabeta6 integrin antagonists as antifibrotic agents
ITRM20030363A0 (en) COMPOSITIONS INCLUDING 3, 5DIIODOTYRONINE AND DIESSE PHARMACEUTICAL USE.
NO20040563L (en) New benzo-condensed heterocycles as endothelin antagonists.
IS2641B (en) 3-Phenyl substituted pyridoindolone, its preparation and therapeutic use.
IS7798A (en) Compounds, pharmaceutical preparations and methods
DK1753725T3 (en) TETRA-HYDRO-ISO-QUINOLINE SULPHONAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC APPLICATION THEREOF.
FI20020881A0 (en) The impactor,
NO20052478D0 (en) Vitamin D analogues, compositions comprising the analogues and their use.
NO20053588L (en) Acylaminothiazole derivatives, their preparation and use as beta-amyloid peptide production inhibitors.
NO20053598L (en) Substituted 1-piperidin-3-yl-4-pyrrolidin-4-yl-piperazine derivatives and their use as neurokinin antagonists.
NO20053805D0 (en) Diarylmethylindenepiperidine derivatives, processes for their preparation, and use thereof
ITTO20030850A1 (en) PROCEDURE FOR THE PREPARATION OF 4-AMINO-3,5-DICLORO-BENZOTRIFLORURO.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application